-
REAL-WORLD COMPARISON OF OLANZAPINE/SAMIDORPHAN VS OLANZAPINE: AN ASSESSMENT OF TREATMENT PATTERNS AND ACUTE CARE EVENTS AMONG PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER
Mar 18, 2026, 21:38 PM -
TYPE 2 COMORBIDITIES IN PATIENTS INITIATING DUPILUMAB FOR ASTHMA: REAL-WORLD EVIDENCE FROM A NATIONAL US DATABASE
Mar 18, 2026, 21:38 PM -
BRIDGING HER2 TESTING AND TREATMENT: REAL-WORLD EVIDENCE ACROSS 22 SOLID TUMORS
Mar 18, 2026, 21:38 PM -
CLAIMS DATABASE ANALYSIS TO ASSESS THE COMPLEXITY AND SEVERITY OF PATIENT CASES, DISEASE BURDEN, AND HEALTH CARE RESOURCE UTILIZATION (HCRU) IN US BARTH SYNDROME PATIENTS
Mar 18, 2026, 21:38 PM -
GIVE ME THE NUMBERS: FINE-GRAINED, STRUCTURED DATA EXTRACTION BEYOND NARRATIVE LLM OUTPUTS
Mar 18, 2026, 21:38 PM -
GLOBAL ASSESSMENT OF THE DIAGNOSED PREVALENCE OF CROHN’S DISEASE AND ULCERATIVE COLITIS IN PEDIATRIC POPULATIONS
Mar 18, 2026, 21:38 PM -
NATIONWIDE COVID-19 TESTING PATTERNS AND DISPARITIES IN POSITIVITY AND ANTIVIRAL TREATMENT IN A U.S. RETAIL PHARMACY CHAIN, SEPTEMBER-DECEMBER 2025
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF FITUSIRAN PROPHYLAXIS VERSUS FACTOR VIII ON-DEMAND OR PROPHYLACTIC THERAPY FOR HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
Mar 18, 2026, 21:38 PM -
AGENTIC PATIENT-REPORTED OUTCOMES (PROS): A CONCEPT-ANCHORED, PATIENT-CENTRIC, HUMAN-IN-THE-LOOP FRAMEWORK FOR AI-AUGMENTED INSTRUMENT DEVELOPMENT
Mar 18, 2026, 21:38 PM -
TEMPORAL TRENDS AND PREDICTORS OF FIRST-LINE CHEMOTHERAPY AMONG OLDER WOMEN DIAGNOSED WITH TRIPLE-NEGATIVE BREAST CANCER IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
UNCOVERING EVIDENCE GAPS IN THE CLINICAL, ECONOMIC, AND HUMANISTIC IMPACT OF DUCHENNE MUSCULAR DYSTROPHY: A COMPREHENSIVE LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
AN EXPANDED ANALYSIS OF WHICH FEATURES CONVEY EMPATHY TO PATIENTS IN SCIENTIFIC WRITING
Mar 18, 2026, 21:38 PM -
ENDOCRINE RESISTANCE AND REAL-WORLD TREATMENT PATTERNS AFTER FIRST-LINE (1L) ET+CDK4/6I IN HR+/HER2-METASTATIC BREAST CANCER (MBC)
Mar 18, 2026, 21:38 PM -
WHEN THERAPIES ARE TARGETED BUT METHODS ARE GUESSING: CLOSING THE GAP IN PRECISION ONCOLOGY EVALUATION
Mar 18, 2026, 21:38 PM -
HOW REPRESENTATIVE ARE LICENSABLE DATASETS COMPARED TO THEIR SOURCE POPULATION
Mar 18, 2026, 21:38 PM -
ACCOUNTING FOR RISK-AVERSION IN HEALTH TECHNOLOGY ASSESSMENT: UTILITY ESTIMATION ACROSS MULTIPLE HEALTH INDEXES IN NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
MARKET SHARE AND ECONOMIC TRENDS OF JANUS KINASE INHIBITORS IN U.S. MEDICAID, 2011- 2023
Mar 18, 2026, 21:38 PM -
IMPACT OF EMERGENCY DEPARTMENT (ED) INVOLVEMENT AT CANCER DIAGNOSIS ON HEALTHCARE COSTS (HCC) ACROSS CANCER TYPES IN THE MEDICARE POPULATION
Mar 18, 2026, 21:38 PM -
INFLUENCING FACTORS ON THE APPROVAL LAG FOR INNOVATIVE DRUGS IN CHINA
Mar 18, 2026, 21:38 PM -
BIREOCICLIB PLUS FULVESTRANT FOR HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS
Mar 18, 2026, 21:38 PM
